Compare 10X Genomics Inc (TXG) vs Sprott Uranium Miners ETF (URNM) Price & Performance

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.

URNM trades at $48.25 with minimal daily movement (+0.06%). The ETF shows bearish technical signals with moving averages indicating selling pressure, though RSI suggests potential oversold conditions. Recent news highlights uranium's role in AI power demand, with nuclear energy positioned as a solution to data center electricity needs. The fund has gained significant attention for its pure-play uranium miner exposure versus broader nuclear ETFs.

The uranium sector faces a favorable long-term outlook with projected nuclear demand tripling by 2050, though current technical weakness and concentration risks in mining companies present near-term challenges. URNM offers leveraged exposure to uranium price movements but remains vulnerable to sector volatility and supply chain constraints.